Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and develops pharmaceutical products in the United States and internationally. Its lead product is AN8025, a tri-functional fusion protein of aPD-L1 x CD86 variant x LAG3 variant, a T-cell and antigen-presenting cell modulator, which is in phase 1a clinical trials for the treatment of tumor. The company also developing AN9025, an oral small molecule pan-RAS(ON) inhibitor, which is in phase 1a clinical trials for the treatment of RAS-mutant cancers include pancreatic, lung, and colorectal adenocarcinomas; and AN4005, a first-in-class oral small-molecule PD-L1 inhibitor, which is in phase 1b treatment for tumor to activate cancer immunity. It is also developing AN0025, a small molecule EP4 antagonist, which is in phase 1b clinical trials for the treatment of locally advanced esophageal cancer (+chemoradiation therapy), and radiotherapy which is in phase 2 clinical trials for the treatment of rectal cancer (+chemoradiation therapy). Adlai Nortye Ltd. was founded in 2004 and is based in Grand Cayman, the Cayman Islands.
Metrics to compare | ANL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipANLPeersSector | |
|---|---|---|---|---|
P/E Ratio | −14.8x | −4.9x | −0.5x | |
PEG Ratio | −0.52 | 0.05 | 0.00 | |
Price / Book | −63.1x | 4.7x | 2.6x | |
Price / LTM Sales | 97.2x | 24.0x | 3.2x | |
Upside (Analyst Target) | 46.7% | 87.4% | 47.6% | |
Fair Value Upside | Unlock | −6.2% | 6.1% | Unlock |